keyword
MENU ▼
Read by QxMD icon Read
search

systemic sclerosis rtx

keyword
https://www.readbyqxmd.com/read/27749242/effects-of-rituximab-in-connective-tissue-disorders-related-interstitial-lung-disease
#1
Gemma Lepri, Jerome Avouac, Paolo Airò, Francisco Anguita Santos, Silvia Bellando-Randone, Jelena Blagojevic, Francisco Garcia Hernàndez, Jose Antonio Gonzalez Nieto, Serena Guiducci, Suzana Jordan, Vidya Limaye, Britta Maurer, Albert Selva-O'Callaghan, Valeria Riccieri, Oliver Distler, Marco Matucci-Cerinic, Yannick Allanore
OBJECTIVES: Interstitial lung disease (ILD) is a key prognostic factor in connective tissue disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional tests (PFTs) in various CTDs, including anti-synthetase syndrome (SYN), systemic sclerosis (SSc) and mixed connective tissue disorder (MCTD), following the use of rituximab therapy. METHODS: A multicentre retrospective analysis of patients with ILD secondary to SYN (n=15), MCTD (n=6) and SSc (n=23)...
September 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27692396/rituximab-for-the-therapy-of-systemic-sclerosis-a-series-of-10-cases-in-a-single-center
#2
Verônica Silva Vilela, Giselle Baptista Maretti, Lívia Marques da Silva Gama, Claudia Henrique da Costa, Rogério Lopes Rufino, Roger A Levy
: Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Although cyclophosphamide is effective for severe and refractory cases, there is demand for new treatments. The biological treatment with B-cell depletion with rituximab (RTX) has demonstrated efficacy for this demand in open-label studies. OBJECTIVE: This study was conducted with the aim to retrospectively evaluate all patients who used RTX for the treatment of SSc in our center...
September 2016: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/27421953/rituximab-for-the-therapy-of-systemic-sclerosis-a-series-of-10-cases-in-a-single-center
#3
Verônica Silva Vilela, Giselle Baptista Maretti, Lívia Marques da Silva Gama, Claudia Henrique da Costa, Rogério Lopes Rufino, Roger A Levy
: Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Although cyclophosphamide is effective for severe and refractory cases, there is demand for new treatments. The biological treatment with B-cell depletion with rituximab (RTX) has demonstrated efficacy for this demand in open-label studies. OBJECTIVE: This study was conducted with the aim to retrospectively evaluate all patients who used RTX for the treatment of SSc in our center...
June 26, 2016: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/27407275/rituximab-induced-neutropenia-in-a-patient-with-inflammatory-myopathy-and-systemic-sclerosis-overlap-disease
#4
Qasim Akram, Mark Roberts, Chester Oddis, Arianne Herrick, Hector Chinoy
Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, it has never been described in a patient with myositis and systemic sclerosis overlap disease. We describe a case of LON in a 54-year-old man who was diagnosed with myositis and then systemic sclerosis overlap disease...
2016: Reumatologia
https://www.readbyqxmd.com/read/27208972/b-cell-depletion-therapy-upregulates-dkk-1-skin-expression-in-patients-with-systemic-sclerosis-association-with-enhanced-resolution-of-skin-fibrosis
#5
Dimitrios Daoussis, Athanassios Tsamandas, Ioannis Antonopoulos, Alexandra Filippopoulou, Dionysios J Papachristou, Nicholaos I Papachristou, Andrew P Andonopoulos, Stamatis-Nick Liossis
BACKGROUND: Rituximab (RTX) may favorably affect skin and lung fibrosis in patients with systemic sclerosis (SSc); however, the underlying molecular mechanisms remain unknown. We aimed to explore the hypothesis that RTX may mediate its antifibrotic effects by regulating the expression of Dickkopf-1 (Dkk-1), an inhibitor of the Wnt pathway. METHODS: Fourteen patients with SSc and five healthy subjects were recruited. Dkk-1 expression was immunohistochemically assessed in skin biopsies obtained from 11 patients with SSc (8 treated with RTX and 3 with standard treatment), whereas DKK1 gene expression was assessed in 3 patients prior to and following RTX administration...
2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/26324802/interstitial-lung-disease-in-systemic-sclerosis-where-do-we-stand
#6
REVIEW
Susanna Cappelli, Silvia Bellando Randone, Gianna Camiciottoli, Amato De Paulis, Serena Guiducci, Marco Matucci-Cerinic
Interstitial lung disease (ILD) is common in systemic sclerosis (SSc) patients and despite recent advances in the treatment is, at present, the major cause of death. Today, an early diagnosis of ILD is possible, and is mandatory to improve the prognosis of the disease. Pulmonary function tests and high-resolution computed tomography remain the mainstay for the diagnosis of SSc-ILD, but there is a growing interest in lung ultrasound. Recently, the correlation between severity of fibrosis and some peripheral blood biomarkers has been described...
September 2015: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/26209905/rituximab-in-the-treatment-of-patients-with-systemic-sclerosis-our-experience-and-review-of-the-literature
#7
REVIEW
Dilia Giuggioli, Federica Lumetti, Michele Colaci, Poupak Fallahi, Alessandro Antonelli, Clodoveo Ferri
BACKGROUND: The treatment of systemic sclerosis (SSc) represents a great clinical challenge because of the complex disease pathogenesis including vascular, fibrotic, and immune T- and B-lymphocyte-mediated alterations. Therefore, SSc should be treated by combined or sequential therapies according to prevalent clinico-pathogenetic phenotypes. Some preliminary data suggest that rituximab (RTX) may downregulate the B-cell over expression and correlated immunological abnormalities. METHODS: Here, we describe a series of 10 SSc patients (4M and 6F, mean age 46±13...
November 2015: Autoimmunity Reviews
https://www.readbyqxmd.com/read/24801917/successful-experience-of-rituximab-therapy-for-systemic-sclerosis-associated-interstitial-lung-disease-with-concomitant-systemic-lupus-erythematosus
#8
Hayakazu Sumida, Yoshihide Asano, Zenshiro Tamaki, Naohiko Aozasa, Takashi Taniguchi, Takehiro Takahashi, Tetsuo Toyama, Yohei Ichimura, Shinji Noda, Kaname Akamata, Miki Miyazaki, Yoshihiro Kuwano, Koichi Yanaba, Shinichi Sato
Previous studies have demonstrated that B cells play critical roles in autoimmune disorders including systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). However, the effectiveness of rituximab (RTX), a chimeric anti-CD20 antibody, for SSc-associated interstitial lung disease (ILD) or SLE disease activity remains controversial. We herein report an SSc patient with severely progressed ILD and concomitant SLE treated by two cycles of RTX at baseline and half a year later. This treatment improved ILD and SLE activities, along with reduction of dermal sclerosis and serum anti-topoisomerase I antibody levels...
May 2014: Journal of Dermatology
https://www.readbyqxmd.com/read/24442885/effects-and-safety-of-rituximab-in-systemic-sclerosis-an-analysis-from-the-european-scleroderma-trial-and-research-eustar-group
#9
Suzana Jordan, Jörg H W Distler, Britta Maurer, Dörte Huscher, Jacob M van Laar, Yannick Allanore, Oliver Distler
OBJECTIVES: To assess the effects of Rituximab (RTX) on skin and lung fibrosis in patients with systemic sclerosis (SSc) belonging to the European Scleroderma Trial and Research (EUSTAR) cohort and using a nested case-control design. METHODS: Inclusion criteria were fulfilment of American College of Rheumatology classification criteria for SSc, treatment with RTX and availability of follow-up data. RTX-treated patients were matched with control patients from the EUSTAR database not treated with RTX...
June 2015: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/23239037/rituximab-rescue-therapy-in-life-threatening-complications-or-refractory-autoimmune-diseases-a-single-center-experience
#10
Yolanda Braun-Moscovici, Yonatan Butbul-Aviel, Ludmila Guralnik, Kochava Toledano, Doron Markovits, Alexander Rozin, Menahem A Nahir, Alexandra Balbir-Gurman
Rituximab (RTX) is a chimeric anti-CD20 antibody, approved for rheumatoid arthritis (RA) patients who failed anti-Tumor Necrosis Factor therapy. It has been used occasionally for life-threatening autoimmune diseases (AID). We report our center experience in the use of RTX in life-threatening complications or refractory AID. Clinical charts of patients treated with RTX at our center were reviewed, cases treated for life-threatening complications or refractory AID were analyzed. Acute damage to vital organs such as lung, heart, kidney, nervous system with severe functional impairment were defined as life-threatening complications; treatment failure with high-dose corticosteroids, cyclophosphamide, IVIG, plasmapheresis was defined as refractory autoimmune disease...
June 2013: Rheumatology International
https://www.readbyqxmd.com/read/23118116/two-year-results-of-an-open-pilot-study-of-a-2-treatment-course-with-rituximab-in-patients-with-early-systemic-sclerosis-with-diffuse-skin-involvement
#11
Vanessa Smith, Yves Piette, Jens T van Praet, Saskia Decuman, Ellen Deschepper, Dirk Elewaut, Filip De Keyser
OBJECTIVE: To study safety and potential efficacy of a 2-treatment course (month 0/6) with rituximab (RTX) in early diffuse systemic sclerosis (dcSSc). METHODS: Two years' followup (open-label study) was done of 8 patients with early dcSSc. Patients received an infusion of 1000 mg RTX 2 times at months 0 and 6, with 100 mg methylprednisolone. Clinical measurements, Disease Activity Score, functional status, and CD19+ peripheral blood count were performed at months 0, 3, 6, 12, 15, 18, and 24 and histopathological evaluation of the skin at months 0, 3, 12, and 24...
January 2013: Journal of Rheumatology
https://www.readbyqxmd.com/read/22697462/b-cell-depletion-therapy-in-patients-with-diffuse-systemic-sclerosis-associates-with-a-significant-decrease-in-pdgfr-expression-and-activation-in-spindle-like-cells-in-the-skin
#12
Dimitrios Daoussis, Athanassios C Tsamandas, Stamatis-Nick C Liossis, Ioannis Antonopoulos, Elli Karatza, Georgios Yiannopoulos, Andrew P Andonopoulos
INTRODUCTION: Recently, several studies assessing the clinical efficacy of rituximab (RTX) in systemic sclerosis (SSc) have reported encouraging results. We aimed at exploring whether RTX exerts its beneficial effects on fibrosis through attenuation of platelet-derived growth factor receptor (PDGFR) pathway activation. METHODS: We immunohistochemically assessed skin biopsies obtained from eight patients with SSc prior to and 6 months following RTX treatment, three control SSc patients (at the same time points) and three healthy subjects...
2012: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/22244622/effect-of-long-term-treatment-with-rituximab-on-pulmonary-function-and-skin-fibrosis-in-patients-with-diffuse-systemic-sclerosis
#13
Dimitrios Daoussis, Stamatis-Nick C Liossis, Athanassios C Tsamandas, Christina Kalogeropoulou, Fotini Paliogianni, Chaido Sirinian, Georgios Yiannopoulos, Andrew P Andonopoulos
OBJECTIVES: To assess the safety and efficacy of long-term treatment with rituximab (RTX) in patients with systemic sclerosis (SSc). METHODS: Eight patients with SSc-associated interstitial lung disease (ILD) received 4 cycles of RTX and had a follow-up of 2 years. Lung involvement was assessed by pulmonary function tests and chest HRCT. Skin involvement was assessed both clinically and histologically. RESULTS: We found a linear improvement of lung function and skin thickening over the 2 years of RTX treatment...
March 2012: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/21826145/b-cell-depletion-therapy-in-systemic-sclerosis-experimental-rationale-and-update-on-clinical-evidence
#14
Dimitrios Daoussis, Stamatis-Nick C Liossis, Georgios Yiannopoulos, Andrew P Andonopoulos
Systemic sclerosis (SSc) is a systemic rheumatic disease with poor prognosis since therapeutic options are limited. Recent evidence from animal models suggests that B-cells may be actively involved in the fibrotic process. B-cells from tight skin mice, an animal model of scleroderma, display a "hyperresponsive" phenotype; treatment with rituximab (RTX) significantly attenuates skin fibrosis in this animal model. In humans, B-cell infiltration is a prominent finding in most lung biopsies obtained from patients with SSc-associated interstitial lung disease...
2011: International Journal of Rheumatology
https://www.readbyqxmd.com/read/20004954/is-there-a-role-for-b-cell-depletion-as-therapy-for-scleroderma-a-case-report-and-review-of-the-literature
#15
REVIEW
Dimitrios Daoussis, Stamatis-Nick C Liossis, Athanassios C Tsamandas, Christina Kalogeropoulou, Alexandra Kazantzi, Panagiotis Korfiatis, Georgios Yiannopoulos, Andrew P Andonopoulos
OBJECTIVES: Rituximab (RTX) has been successfully used in the treatment of several rheumatic diseases with an acceptable safety profile. We present herein a patient with systemic sclerosis (SSc) who exhibited significant improvement of his lung function and skin fibrosis following RTX administration, and review the literature regarding the role of B-cells in SSc and the potential efficacy of RTX in its treatment. METHODS: We performed an internet search using the keywords systemic sclerosis, scleroderma, rituximab, B-cells, fibrosis, interstitial lung disease (ILD), and therapy...
October 2010: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/19000786/a-review-of-the-current-use-of-rituximab-in-autoimmune-diseases
#16
REVIEW
Hakan M Gürcan, Derin B Keskin, Joel N H Stern, Matthew A Nitzberg, Haris Shekhani, A Razzaque Ahmed
Rituximab is a human/murine chimeric monoclonal antibody primarily used for treating non-Hodgkin's B-cell lymphoma. Recently it has also been used in the treatment of several autoimmune diseases. A literature review was conducted to determine the efficacy of rituximab in the treatment of some of these autoimmune diseases. Multiple mechanisms proposed for the rituximab mediated B cell depletion are also discussed. The efficacy of rituximab is well-established and it is FDA approved for treatment of Rheumatoid arthritis...
January 2009: International Immunopharmacology
https://www.readbyqxmd.com/read/14992337/intravesical-resiniferatoxin-for-refractory-detrusor-hyperreflexia-a-multicenter-blinded-randomized-placebo-controlled-trial
#17
RANDOMIZED CONTROLLED TRIAL
Jang Hwan Kim, David A Rivas, Patrick J Shenot, Bruce Green, Michael Kennelly, Janet R Erickson, Margie O'Leary, Naoki Yoshimura, Michael B Chancellor
OBJECTIVE: Resiniferatoxin (RTX) is an analogue of capsaicin with more than 1,000 times its potency in desensitizing C-fiber bladder afferent neurons. This study investigated the safety and efficacy of intravesical RTX in patients with refractory detrusor hyperreflexia (DH). METHODS: Thirty-six (22 males, 14 females) neurologically impaired patients (20 spinal cord injury, 7 multiple sclerosis, 9 other neurologic diseases) with urodynamically verified DH and intractable urinary symptoms despite previous anticholinergic drug use were treated prospectively with intravesical RTX using dose escalation in a double-blind fashion at 4 centers...
2003: Journal of Spinal Cord Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"